CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Sarah Jimenez, DNP, AGACNP-BC, AOCNP
BMT/IEC Advanced Practice Provider
Blood and Marrow Transplantation/Immune Effector Cell Therapy Program
Augusta University/Georgia Cancer Center

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

CAR T-Cell Therapy Resource Center

Interview with Liza Rodriguez, DNP, E-MBA, APRN, AOCNP: Survivorship Care Post CAR T-Cell Therapy

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

Lymphoma Research Foundation: Treatment Options: CAR T-Cell Therapy

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets